OBJECTIVE: Although in benign multiple sclerosis (BMS) locomotor disability is absent or only minimal, subclinical cognitive impairment seems to occur in many cases. Diffusion tensor (DT) MRI enables us to quantify the extent of "actual" tissue damage, which goes undetected when using conventional MRI. Against this background, we investigated the extent of structural brain damage underlying cognitive dysfunction in BMS, with the ultimate aim to move a first step toward a more reliable definition of this disease phenotype. METHODS: Conventional and DT MRI scans of the brain were acquired from 62 BMS patients. Thirty-six secondary progressive multiple sclerosis (SPMS) patients and 19 healthy subjects served as controls. In BMS patients, neuropsychological tests exploring memory, attention, and frontal lobe functions were administered. Normalized brain volume (NBV), mean diffusivity (MD), and fractional anisotropy (FA) of the normal-appearing white matter (NAWM) and MD of the gray matter (GM) were computed. RESULTS: Twelve BMS patients (19%) fulfilled predefined criteria for cognitive impairment. BMS patients had abnormal MD and FA values from both NAWM and GM. Whereas BMS patients without cognitive impairment had lower T2 LV (p = 0.03), higher NBV (p = 0.006), and lower average GM MD (p = 0.03) than SPMS patients, BMS patients with cognitive impairment did not significantly differ from SPMS patients for any MRI-derived metric. CONCLUSIONS: In benign multiple sclerosis (BMS), cognitive dysfunction is associated with severe structural brain damage, which resembles that of patients with a much more disabling disease course. A reliable definition of BMS should, therefore, include the preservation of cognitive functioning as an additional requisite.
OBJECTIVE: Although in benign multiple sclerosis (BMS) locomotor disability is absent or only minimal, subclinical cognitive impairment seems to occur in many cases. Diffusion tensor (DT) MRI enables us to quantify the extent of "actual" tissue damage, which goes undetected when using conventional MRI. Against this background, we investigated the extent of structural brain damage underlying cognitive dysfunction in BMS, with the ultimate aim to move a first step toward a more reliable definition of this disease phenotype. METHODS: Conventional and DT MRI scans of the brain were acquired from 62 BMS patients. Thirty-six secondary progressive multiple sclerosis (SPMS) patients and 19 healthy subjects served as controls. In BMS patients, neuropsychological tests exploring memory, attention, and frontal lobe functions were administered. Normalized brain volume (NBV), mean diffusivity (MD), and fractional anisotropy (FA) of the normal-appearing white matter (NAWM) and MD of the gray matter (GM) were computed. RESULTS: Twelve BMS patients (19%) fulfilled predefined criteria for cognitive impairment. BMS patients had abnormal MD and FA values from both NAWM and GM. Whereas BMS patients without cognitive impairment had lower T2 LV (p = 0.03), higher NBV (p = 0.006), and lower average GM MD (p = 0.03) than SPMS patients, BMS patients with cognitive impairment did not significantly differ from SPMS patients for any MRI-derived metric. CONCLUSIONS: In benign multiple sclerosis (BMS), cognitive dysfunction is associated with severe structural brain damage, which resembles that of patients with a much more disabling disease course. A reliable definition of BMS should, therefore, include the preservation of cognitive functioning as an additional requisite.
Authors: Bianca Weinstock-Guttman; Steven L Galetta; Gavin Giovannoni; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; Paul W O'Connor; J Theodore Phillips; Chris Polman; William H Stuart; Frances Lynn; Christophe Hotermans Journal: J Neurol Date: 2011-10-19 Impact factor: 4.849
Authors: M A Rocca; G Riccitelli; M Rodegher; A Ceccarelli; A Falini; M Falautano; A Meani; G Comi; Massimo Filippi Journal: AJNR Am J Neuroradiol Date: 2010-03-18 Impact factor: 3.825
Authors: Kristin M Galetta; Jennifer Graves; Lauren S Talman; Deacon J Lile; Elliot M Frohman; Peter A Calabresi; Steven L Galetta; Laura J Balcer Journal: J Neuroophthalmol Date: 2012-06 Impact factor: 3.042
Authors: D J Rigotti; A Gass; L Achtnichts; M Inglese; J S Babb; Y Naegelin; J Hirsch; M Amann; L Kappos; O Gonen Journal: Mult Scler Date: 2011-09-15 Impact factor: 6.312
Authors: M Filippi; M A Rocca; R H B Benedict; J DeLuca; J J G Geurts; S A R B Rombouts; M Ron; G Comi Journal: Neurology Date: 2010-12-07 Impact factor: 9.910
Authors: James M Stankiewicz; Bonnie I Glanz; Brian C Healy; Ashish Arora; Mohit Neema; Ralph H B Benedict; Zachary D Guss; Shahamat Tauhid; Guy J Buckle; Maria K Houtchens; Samia J Khoury; Howard L Weiner; Charles R G Guttmann; Rohit Bakshi Journal: J Neuroimaging Date: 2011-04 Impact factor: 2.486